Table 1 Clinical and tumor characteristics
| Â | BRCA1 n(%) | BRCA2 n(%) | BRCAX n(%) | All familial n(%) |
|---|---|---|---|---|
Age | Â | Â | Â | Â |
≤ 50 years | 25 (89%) | 15 (56%) | 24 (61%) | 64 (68%) |
> 50 years | 3 (11%) | 12 (44%) | 15 (39%) | 30 (32%) |
Tumor size | Â | Â | Â | Â |
< 20 mm | 20 (71%) | 13 (52%) | 16 (47%) | 49 (56%) |
> 20 mm | 8 (29%) | 12 (48%) | 18 (53%) | 38 (44%) |
Unknown | 0 | 2 | 5 | 7 |
Nodal status | Â | Â | Â | Â |
Negative | 26 (93%) | 19 (70%) | 25 (64%) | 70 (74%) |
Positive | 2 (7%) | 8 (30%) | 14 (36%) | 24 (26%) |
Unknown | 0 | 0 | 0 | 0 |
Grade | Â | Â | Â | Â |
I | 0 | 1 (4%) | 2 (6%) | 3 (4%) |
II | 2 (9%) | 10 (44%) | 8 (24%) | 20 (25%) |
III | 21 (93%) | 12 (52%) | 23 (70%) | 56 (71%) |
Unknown | 5 | 4 | 6 | 15 |
ERα |  |  |  |  |
Negative | 23 (85%) | 5 (21%) | 11 (32%) | 39 (46%) |
Positive | 4 (15%) | 19 (79%) | 23 (68%) | 46 (54%) |
Unknown | 1 | 3 | 5 | 9 |
PgR | Â | Â | Â | Â |
Negative | 23 (85%) | 9 (38%) | 16 (47%) | 48 (56%) |
Positive | 4 (15%) | 15 (62%) | 18 (53%) | 37 (44%) |
Unknown | 1 | 3 | 5 | 9 |
HER2 status | Â | Â | Â | Â |
Negative | 26 (100%) | 22 (100%) | 28 (85%) | 76 (94%) |
Positive | 0 | 0 | 5 (15%) | 5 (6%) |
Unknown | 2 | 5 | 6 | 13 |
Endocrine therapy | Â | Â | Â | Â |
Not given | 22 (96%) | 16 (76%) | 21 (64%) | 59 (77%) |
Given | 1 (4%) | 5 (24%) | 12 (36%) | 18 (23%) |
Unknown | 5 | 6 | 6 | 17 |
Chemotherapy | Â | Â | Â | Â |
Not given | 8 (30%) | 15 (60%) | 13 (39%) | 16 (42%) |
Given | 19 (70%) | 10 (40%) | 20 (61%) | 49 (58%) |
Unknown | 1 | 2 | 6 | 9 |